Diane de Vos-Schmidt
Community Health · San Luis Obispo, CANPI 1790176543
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.8% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,014 and has fallen 80.9% since, to $194 in 2025. Among community health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $25.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$266
- Astellas Pharma US Inc$221
- Sanofi-aventis U.S. LLC$177
- Travere Therapeutics, Inc.$147
- GSK$123
- Fresenius USA Marketing, Inc.$117
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,13492%
- Education$1918%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $266 |
| Astellas Pharma US Inc | 15 | $221 |
| Sanofi-aventis U.S. LLC | 2 | $177 |
| Travere Therapeutics, Inc. | 2 | $147 |
| GSK | 5 | $123 |
| Fresenius USA Marketing, Inc. | 1 | $117 |
| Ardelyx, Inc. | 1 | $116 |
| Novartis | 5 | $103 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $102 |
| Eisai Inc. | 5 | $98 |
| Secura Bio, Inc. | 1 | $93 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Sanofi | 3 | $69 |
| Merck | 3 | $64 |
| Johnson & Johnson | 3 | $63 |
| Amgen | 3 | $55 |
| Pfizer | 2 | $36 |
| Puma Biotechnology, Inc. | 2 | $34 |
| AstraZeneca | 2 | $34 |
| Seagen Inc. | 1 | $33 |
| Acrotech Biopharma Inc. | 2 | $30 |
| Gilead | 1 | $27 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $21 |
| Deciphera Pharmaceuticals Inc. | 1 | $20 |
| EMD Serono, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $19 |
| Dova Pharmaceuticals | 1 | $17 |
| Akebia Therapeutics Inc | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Array Biopharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Velphoro$117
- XPHOZAH 30 MG$116
How this compares
$2,325 in reported general payments places this provider in the 95th percentile of 74 community health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 59 | $51,011 |
| FarxigaDapagliflozin Propanediol | 56 | $41,946 |
| VelphoroSucroferric Oxyhydroxide | 13 | $37,315 |
| Sevelamer Carbonate | 18 | $7,103 |
| Calcitriol | 62 | $1,959 |
| Allopurinol | 151 | $1,614 |
| Lisinopril | 79 | $839 |
| Losartan Potassium | 80 | $676 |
| Nifedipine ErNifedipine | 15 | $523 |
| Furosemide | 48 | $488 |
| Amlodipine Besylate | 47 | $321 |
| Metoprolol Succinate | 12 | $234 |
| Chlorthalidone | 12 | $195 |
| Hydrochlorothiazide | 32 | $114 |
| Metoprolol Tartrate | 13 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $19 | $51,01159 claims |
| AstraZenecaFarxiga | $34 | $41,94656 claims |
| Fresenius USA Marketing, Inc.Velphoro | $117 | $37,31513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 74 community health providers in California.
Other community health in San Luis Obispo
- Maria LascunaReedley$6K
- Mi ChangLos Angeles$2K
- Karen JenneLos Angeles$2K
- Lanelle LapigSherman Oaks$2K
- Loann PhanSanta Ana$1K
- Emily NjorogeMerced$1K
- Jasmine RuizEast Palo Alto$808
- Montserrat NoboaSan Diego$789
- Carrie GerdikSun City$778
- Lily KhoshabaWinton$694
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.